Hematology, the study of normal and diseased blood elements and their interaction with the vasculature in which they reside, is a fertile research field, in no small part due to the enviable access of hematologic researchers to primary tissues. Nonetheless, despite remarkable breakthroughs in our understanding of the molecular basis for a wide variety of hematologic illnesses, there remains a gap between our current knowledge and our ability to substantively alter the course of these diseases. The goals of the BUSM Hematology Training Program (HTP) are to attract talented researchers to a hematologic research project, to inspire them to choose some aspect of hematology for their subsequent research careers, and to give them the knowledge base, the technical skills and the grant-writing ability to be able to establish themselves as independent researchers in an academic setting. Our proposed training program, which has been existence since 1980, will train four pre-doctoral students and four post-doctoral students, the latter with either PhD (2) or MD (2) degrees. Trainees will be mentored by a select group of 18 faculty whose research interests are particularly strong in the following four areas: Hemoglobinopathies, Immunotherapy and Immunopathology, Lymphoid Cell Signaling and Gene Expression, and Platelet and Thrombosis Biology. Pre-doctoral students enrolled in established basic science programs such as Biochemistry, Microbiology or Molecular Medicine typically apply to the HTP executive committee during their second year of graduate school. Both pre-doctoral students and post- doctoral fellows attend Hematology Journal Club, Hematology Grand Rounds and a Molecules to Molecular Therapeutics course which is an in depth study of hemoglobinopathies. By fostering an atmosphere in which clinicians and basic science researchers work in close collaboration, our program will train the next generation of hematology researchers to identify practical therapeutic approaches that will close the gap between our knowledge of the molecular basis for hematologic illness and its successful treatment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007501-31
Application #
8319418
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Chang, Henry
Project Start
1980-07-01
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
31
Fiscal Year
2012
Total Cost
$314,738
Indirect Cost
$26,081
Name
Boston University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Tan, Ying; Watkins, Amanda A; Freeman, Benjamin B et al. (2015) Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. J Immunol 194:101-12
Alsultan, Abdulrahman; Alabdulaali, Mohammed K; Griffin, Paula J et al. (2014) Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign. Br J Haematol 164:597-604
Belfer, Inna; Youngblood, Victoria; Darbari, Deepika S et al. (2014) A GCH1 haplotype confers sex-specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia. Am J Hematol 89:187-93
Haery, Leila; Lugo-Picó, Julián G; Henry, Ryan A et al. (2014) Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth. Mol Cancer 13:29
Griffin, Paula J; Sebastiani, Paola; Edward, Heather et al. (2014) The genetics of hemoglobin A2 regulation in sickle cell anemia. Am J Hematol 89:1019-23
Milton, Jacqueline N; Gordeuk, Victor R; Taylor 6th, James G et al. (2014) Prediction of fetal hemoglobin in sickle cell anemia using an ensemble of genetic risk prediction models. Circ Cardiovasc Genet 7:110-5
Yang, Sung; Stepien, David; Hanseman, Dennis et al. (2014) Substance P mediates reduced pneumonia rates after traumatic brain injury. Crit Care Med 42:2092-100
Anderson, N M; Harrold, I; Mansour, M R et al. (2014) BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia 28:1145-8
Thompson, Ryan C; Vardinogiannis, Iosif; Gilmore, Thomas D (2013) Identification of an NF-*B p50/p65-responsive site in the human MIR155HG promoter. BMC Mol Biol 14:24
Barbosa, Cynara G; Aleluia, Augusto C M; Pacheco, Ana P A S et al. (2013) Genetic modulation of HbF in Brazilians with HbSC disease and sickle cell anemia. Am J Hematol 88:923-4

Showing the most recent 10 out of 64 publications